FGF19 Antibody - #DF2651

(3)   (3)  
製品: FGF19 Antibody
カタログ: DF2651
タンパク質の説明: Rabbit polyclonal antibody to FGF19
アプリケーション: WB IHC
反応性: Human, Rat
予測: Pig, Zebrafish, Bovine, Rabbit, Dog
分子量: 24 kDa; 24kD(Calculated).
ユニプロット: O95750
RRID: AB_2839857

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MS Report
HPLC Report
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Rat
予測:
Pig(92%), Zebrafish(89%), Bovine(90%), Rabbit(92%), Dog(83%)
クローナリティ:
Polyclonal
特異性:
FGF19 Antibody detects endogenous levels of total FGF19.
RRID:
AB_2839857
引用形式: Affinity Biosciences Cat# DF2651, RRID:AB_2839857.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

FGF 19; FGF-19; FGF15; FGF19; FGF19_HUMAN; Fibroblast growth factor 15; Fibroblast growth factor 19;

免疫原

免疫原:
Uniprot:

O95750(FGF19_HUMAN) >>Visit HPA database.

遺伝子(ID):
FGF19(9965)
発現特異性:
O95750 FGF19_HUMAN:

Expressed in fetal brain, cartilage, retina, and adult gall bladder.

タンパク質の説明:
Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB.;
タンパク質配列:
MRSGCVVVHVWILAGLWLAVAGRPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Rabbit
92
Pig
92
Bovine
90
Zebrafish
89
Dog
83
Horse
0
Sheep
0
Xenopus
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - O95750 基板として

Site PTM Type Enzyme
K93 Methylation
S185 Phosphorylation
S189 Phosphorylation

研究背景

機能:

Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4.

細胞の位置付け:

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed in fetal brain, cartilage, retina, and adult gall bladder.

サブユニット構造:

Interacts with FGFR1, FGFR2, FGFR3 and FGFR4. Affinity between fibroblast growth factors (FGFs) and their receptors is increased by KL, KLB and heparan sulfate glycosaminoglycans that function as coreceptors. Interacts with KL; this interaction is direct. Interacts with KLB; this interaction is direct. Interacts with FGFR4 in the presence of heparin, KL or KLB. Interacts with MALRD1.

タンパク質ファミリー:

Belongs to the heparin-binding growth factors family.

研究領域

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

参考文献

1). Silibinin, a commonly used therapeutic agent for non-alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19. British journal of pharmacology, 2024 (PubMed: 38839561) [IF=7.3]
2). Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway. Frontiers in Pharmacology, 2022 (PubMed: 36278226) [IF=5.6]

Application: WB    Species: Rat    Sample:

FIGURE 6 EPC ameliorated MAFLD formation in rats by regulating BA metabolism. (A–G) Relative expression of CYP7A1, FXR, CYP27A1, BSEP, CYP7B1, CYP8B1, NTCP mRNA in liver, n = 6; (H–L) Relative expression of protein CYP7A1, FXR, SHP, p-AMPK, and p-ERK in the liver, n = 4; (M–N) Relative expression of protein FXR and FGF15 in the ileum, n = 4. (O–P) Representative immunoblotting images of CYP7A1, FXR, SHP, p-AMPK,and p-ERK in the liver. (Q) Representative immunoblotting images of FXR and FGF15 in the ileum. Data are presented as mean ± SEM. One-way analysis of variance (ANOVA) was conducted for the group comparison. *p < 0.05, **p < 0.01, ***p < 0.001 vs. MOD group. CYP7A1, cholesterol 7α-hydroxylase; FXR, farnesoid X receptor; CYP27A1, sterol 27-hydroxylase; BSEP, bile salt export protein; CYP7B1, oxysterol 7α-hydroxylase; CYP8B1, sterol 12αhydroxylase; NTCP, Na + -taurocholate co-transporting polypeptides; SHP, small heterodimer partner; AMPK, 5’-AMP-activated protein kinase; ERK, Extracellular signal-regulated kinase.
3). Downregulation of serum and distal ileum fibroblast growth factor19 in bile acid diarrhoea patients. DIGESTIVE DISEASES AND SCIENCES, 2022 (PubMed: 34041651) [IF=3.1]

Application: IHC    Species: Human    Sample: ileum tissue

Fig. 5 Expression of FGF19 of the terminal ileum in chronic diar- rhoea patients. a, b A positive immunoperoxidase reaction was observed in the cytoplasmatic compartment of terminal ileum mucosa epithelial cells, and some gland cells in the lamina propria. Ileum enterocytes showed FGF19 signal from apical to basal domains, espe-cially in the apical domains. c, d The staining intensity was divided into 2 categories (c pale brown = 1; d brown = 2). e–g The percentage of immunoreactive cells were calculated and classified on a 3-point scale (e 1–33% = 1; f 34–66% = 2; g 67–100% = 3)

Application: IHC    Species: human    Sample: terminal ileum mucosa epithelial cells

Fig. 5| Expression of FGF19 of the terminal ileum in chronic diarrhoea patients. a, b A positive immunoperoxidase reaction was observed in the cytoplasmatic compartment of terminal ileum mucosa epithelial cells, and some gland cells in the lamina propria. Ileum enterocytes showed FGF19 signal from apical to basal domains, especially in the apical domains.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.